Following our previous podcast, which delved into the evolution of home high-flow therapy (HFT) and its implications for patient care, Dr Maxime Patout returns to offer more insights into the topic. This time round he describes the objectives of the large HiFAE trial he’s leading to assess the benefit of HFT when initiated after a severe exacerbation of COPD. Focused on French patients with severe forms of the condition, the study – which saw its first patient enrolled in late 2022 – aims to show that using HFT in a home setting can indeed decrease both the rate of exacerbations and mortality, as well as improve quality of life and respiratory function. Listen now to find out more!

Guest:

• Dr Maxime Patout - Hospital Pitié Salpêtrière, Faculty of Medicine, Sorbonne University, France.

Host:

• Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care.

Disclaimers:

• This content is intended for health professionals only.
• This testimonial is a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. This presentation is based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art.
• Dr Maxime Patout was provided with a nominal financial incentive for providing the following testimonial. Dr Maxime Patout will not receive any discounts or further incentives as a result of this testimonial.

Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in respiratory care and sleep-disordered breathing.

© ResMed